Expanding the phenotype of MTOR -related disorders and the Smith-Kingsmore syndrome

Abstract

Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article. The Article Processing Charge was funded by the Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

A new case of Smith‐Kingsmore syndrome with somatic MTOR pathogenic variant expands the phenotypic spectrum to lateralized overgrowth

“…Among them, the c.5395G > A p.Glu1799Lys variant was found in nearly half of the cases (14 of 34) and represents a mutational hotspot 15 . Among the patients reported, 29 carried germline pathogenic variants, either de novo or deriving from gonadal mosaicism, 1,11‐13 while five patients presented mosaic variants in at least two of the tissues tested (disseminated mosaicism) 1,6‐8 . The main clinical features of these patients are summarized in Table 1 and compared with our case.…”

“…Since SKS was first described, and to the best of our knowledge, 12 pathogenic MTOR variants in 34 patients have been reported in the medical literature, 1,7,11‐13 all of which were gain‐of‐function missense variants 1,2,12‐15 . Among them, the c.5395G > A p.Glu1799Lys variant was found in nearly half of the cases (14 of 34) and represents a mutational hotspot 15 .…”

Delineating the Smith‐Kingsmore syndrome phenotype: Investigation of 16 patients with the MTOR c.5395G > A p.(Glu1799Lys) missense variant

“…This variant has been shown to decrease the binding of the mTOR inhibitor Deptor, thereby upregulating the mTOR pathway and promoting growth (Baynam et al, 2015;Gordo et al, 2018). Ten additional MTOR missense variants, targeting amino acid residues within the FAT and kinase domains, have been described in the remaining 16 patients reported in the literature (Allen et al, 2013;Elizondo-Plazas et al, 2020;Ghahramani et al, 2015;Gordo et al, 2018;Møller et al, 2016;Rodríguez-García et al, 2019;Smith et al, 2013) (Figure 1). There are limited functional data available on these 10 other variants but a gain of function effect has been ascribed to the MTOR c.4448G>T p.(Cys1483Phe) variant (Gordo et al, 2018;Grabiner et al, 2014;Smith et al, 2013).…”

“…In 2013, constitutional MTOR variants were reported to cause a new OGID syndrome, eponymously named Smith-Kingsmore Syndrome (SKS) (OMIM 616638) (Smith et al, 2013). Since this initial description, a total of 30 patients with constitutional MTOR variants have been described, with clinical features including megalencephaly, a variable intellectual disability, autism spectrum disorder, and seizures (Allen et al, 2013;Baynam et al, 2015;Elizondo-Plazas et al, 2020;Ghahramani et al, 2015;Gordo et al, 2018;Lee et al, 2019;Mirzaa et al, 2016;Møller et al, 2016;Moosa et al, 2017;Mroske et al, 2015;Rodríguez-García et al, 2019;Smith et al, 2013).…”